SNS 062

Drug Profile

SNS 062

Alternative Names: SNS-062

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Biogen; Sunesis Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 30 Jan 2017 US FDA approves IND application for SNS 062 in Haematological malignancies
  • 05 Dec 2016 Sunesis completes a phase I trial in Haematological malignancies in Belgium (PO)
  • 05 Dec 2016 Updated pharmacokinetics data from a phase Ia trial in Healthy volunteer presented at the 58th American Society of Hematology Annual Meeting (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top